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its inhibition of histone deacetylases
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Departments of Pharmacology and Anesthesiology, New York Medical College, Valhalla, New York, United
States of America
* mario_inchiosa@nymc.edu
Abstract
The principal finding from this study was the recognition that the α-adrenergic antagonist,
phenoxybenzamine, possesses histone deacetylase inhibitory activity. Phenoxybenzamine
is approved by the United States Food and Drug Administration for the treatment of hyper-
tensive crises associated with tumors of the adrenal medulla, pheochromocytomas. It has
several “off label” indications relative to its capacity to relax vascular smooth muscle and
smooth muscle of the urogenital tract. The drug also has a long history of apparent efficacy
in ameliorating, and perhaps reversing, the severe symptoms of neuropathic pain syn-
dromes. Our interest in this feature of the drug relates to the fact that certain types of neuro-
pathic pain, in particular complex regional pain syndrome, demonstrate a proliferative
nature, with the capacity to spread from an injured limb, for example, to a non-injured limb
and perhaps to essentially the entire body. Sensory neuronal sprouting in the spinal cord
has been observed under conditions where there is a high sensory input from painful stimuli.
Searches of gene expression signatures in the BroadBuild02 Molecular Signature Database
using their connectivity map software suggested that phenoxybenzamine may have histone
deacetylase inhibitory activity. Studies by others have reported inhibitory effects of phenoxy-
benzamine on growth, invasion and migration of human tumor cell cultures and, in one
study, inhibition of tumor expansion in animal experiments. Inhibitory effects on human
tumor cell cultures are also reported in the present study. Phenoxybenzamine was also
found to have histone deacetylase inhibitory activity; histone deacetylase isoforms 5, 6, and
9 were the most sensitive to inhibition by phenoxybenzamine. The importance of elevated
levels of these isoforms as biomarkers of poor prognosis in human malignant disease, and
the recognized suppression of tumor growth that may accrue from their inhibition, opens
consideration of possible translation of phenoxybenzamine to new clinical applications. This
might be facilitated by the fact that phenoxybenzamine is already an approved drug entity.
There appears to be no previous report of the activity of phenoxybenzamine as a histone
deacetylase inhibitor.
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Introduction
Phenoxybenzamine (PBZ) is classified chemically as a haloalkylamine (Fig 1). It was approved
in 1953 by the United States Food and Drug Administration (FDA) for the treatment of hyper-
tensive emergencies, in particular for the control of blood pressure in patients secreting large
quantities of epinephrine and norepinephrine from tumors of the adrenal medulla, termed
pheochromocytomas. Its United States proprietary name is Dibenzyline, but generic prepara-
tions are available. The drug forms covalent bonds with α1- and α2—adrenergic receptors
resulting in a long-lasting non-competitive antagonism of these receptors. The drug has addi-
tional (non-FDA-labeled) indications related to its relaxing effects on vascular smooth muscle
in peripheral vascular diseases and the smooth muscle of the urogenital tract (http://www.
ahfsdruginformation.com) [1].
Interest in the potential anti-proliferative activity of PBZ evolved from observations of its
apparent efficacy in the treatment of the chronic neuropathic pain syndrome, Complex
Regional Pain Syndrome (CRPS), which was previously termed Reflex Sympathetic Dystrophy.
An initial study was based on the known non-competitive (irreversible) alpha-adrenergic
antagonist activity of PBZ against the mediators of the sympathetic nervous system, norepi-
nephrine and epinephrine, in an attempt to antagonize the presumed sympathetic dystrophy
[2,3]. Apparent efficacy was observed in this small human study. This first study employed an
investigational intravenous formulation of PBZ, but further work was precluded by the lack of
availability of a stable intravenous formulation; there is still no preparation available today.
In a subsequent series of case reports with the FDA-approved oral preparation of the drug,
there was again observed apparent efficacy for treatment of CRPS and an hypothesis was pre-
sented for possible mechanisms of action in this syndrome [4]. It was noted in this report that
in addition to its alpha-adrenergic antagonist activity, PBZ was also a potent non-competitive
(irreversible) inhibitor of calmodulin, and integrated this activity into its efficacy in CRPS. An
anti-inflammatory/immunomodulatory mechanism of action for the drug was included in a
later review [5].
A study by Chang et al. [6] added considerable support to the possible therapeutic value of
PBZ for the treatment of CRPS. They identified patterns of genes that were differentially
expressed in the Complete Freund’s Adjuvant (CFA) animal model of CRPS. This model
results in tactile allodynia and thermal hyperalgesia. Gene map arrays from RNA extracts of
the L4 and L5 dorsal root ganglia of rats that had received intraplantar CFA for 4 days revealed
more than 100 genes that were significantly (> 1.5 fold; p 0.05) up- or down-regulated. The
genes involved immune function, inflammatory response, and neuronal growth. The total pat-
tern of gene changes was considered to be a gene “signature” of the CFA model. Their search
of the Broad Build02 database [7] for pharmacologically active compounds that had strong
inverse gene signatures in relation to that of the CFA pathology yielded PBZ as one of five
compounds with the strongest inverse matches of gene expression. The inverse signature sug-
gested possible therapeutic value in this pain syndrome. They also demonstrated that PBZ was
equipotent with the nonsteroidal anti-inflammatory drug, naproxen, in reversing the height-
ened pain sensitivity of the CFA-affected animals [6].
The relevance of these earlier investigations to this present study relates to the rather
remarkable fact that CRPS appears to have a substantial proliferative component in regard to
both pain severity and expansion of anatomical involvement [8–10]. Thus, it has been
observed that there is an anatomical spread of the pain and associated symptoms in the vast
majority of cases [11]. The spread may be related to reports of sensory neuronal dendritic
sprouting to the dorsal horn of the spinal cord when there is high sensory input [12–14]. It is
this proliferative activity in the syndrome that led to the investigation of the possible anti-
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proliferative activity of PBZ, particularly in relation to possible inhibitory effects on histone
deacetylase (HDAC) activity.
The importance of the epigenetic modulation of gene expression by HDACs and histone
acetyltransferases (HATs) does not need to be reviewed here. The balance between the
actions of HDACs and HATs is extremely complex and the interaction of these effects relates
to many examples of dysregulation of gene expression that are associated with malignant
Fig 1. Chemical structure for phenoxybenzamine HCl.
https://doi.org/10.1371/journal.pone.0198514.g001
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transformation and expansion, and autoimmunity [15]. The initial recognition of PBZ as a
potential inhibitor of HDAC was revealed through searches of the BroadBuild02 (Broad Insti-
tute Harvard/Massachusetts Institute of Technology) Molecular Signature Database (MSigDB)
with the use of their Connectivity Map (CMap) software [7,16]. CMap has gained a broad role
in genomic investigations relative to repurposing of existing drugs, hypothesis testing, mecha-
nisms of action and lead discoveries [17]. The co-sorting of PBZ in CMap with known HDAC
inhibitors was followed up with tests of anti-proliferation of human tumor cell lines, and then
with direct tests for inhibition of HDACs by PBZ.
The chemical structure of PBZ (Fig 1) does not appear to have any particular features that
are similar to known HDAC inhibitors. In fact, the structure of PBZ is distinguished from
known inhibitors by the fact that it is a haloalkylamine, with a substituted chlorine atom; 21
congeners of PBZ have been described, all with chorine as the halogen substitution [18]. These
congeners showed varying potencies in regard to a common property of inhibition of uptake
of catecholamines into presynaptic sympathetic nerve terminals in the isolated rat heart, and
at extraneuronal uptake processes; none of these compounds have been investigated in the
present study.
Materials and methods
PBZ searches on the Harvard-MIT molecular signature database
The open web-based platforms of BroadBuild02 CMap (www.broad.mit.edu/cmap) and
MSigDB (www.broadinstitute.org/gsea/msigdb) were used for all of the genomic expression
searches. Only simple registration is necessary to access these databases and the associated
CMap software. This database consists of approximately 7,000 gene expression profiles for
1309 FDA-approved drugs and other compounds of interest as gene expression modulators.
The profiles (‘instances,” in the BroadBuild terminology) are based almost entirely on the
effects of compounds on MCF7 (breast cancer), PC3 (prostate cancer) and HL60 (leukemia)
cells. The database includes 3 gene expression profiles for PBZ in MCF7 cells and one profile
in PC3 cells. A common core gene expression set resulting from the effects of three HDAC
inhibitors (suberanilohydroxamic acid (SAHA); trichostatin A (TSA) and MS-275) in human
breast cancer cells (MDA 468 and MDA 435) and human bladder cancer cells (T24) [19] was
first evaluated for the relative association of the 4 PBZ gene expression profiles with known
HDAC inhibitors. CMap also provided a measure of the relative selectivity of PBZ for this
common gene expression signature compared with other gene signatures where PBZ was
found to have higher gene enrichment scores than in the common core set noted above [19].
Enrichment scores represent a relative measure of the correspondence between a gene signa-
ture of interest (e.g. a biological state) and a calculated composite measure of the 4 gene
expression profiles of PBZ in CMap [20].
Effects of PBZ on human tumor cell proliferation
The results of these studies were included in an application for the screening of PBZ in the
National Cancer Institute NCI60 screening program (https://dtp.cancer.gov/discovery_
development/nci-60); they measured its effects on growth in cultures of 60 human tumors.
This initial screen was conducted at only one drug concentration, 10 μM. We supplied the
United States Pharmacopeial reference standard of PBZ-hydrochloride in powder form. The
NCI60 standard procedure for dissolution of a synthetic molecule like PBZ involved initial
dilution in 9:1 dimethyl sulfoxide (DMSO): glycerol at a concentration of 4 mM; the solution
was then diluted 1:200 with complete culture medium (RPMI 1640 medium containing
5% fetal calf serum (FCS), 2 mM L-glutamine and 50 μg/ml gentamicin to give a final
Phenoxybenazamine inhibits certain histone deacetylases
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concentration of 20 μM; 100 μl of the drug-medium mixture was added to 100 μl of the cell
cultures already in complete medium. The microtiter plates were incubated for 48 hr at 37˚C,
5% CO2, 95% air, and 100% relative humidity (see S1 Appendix for further details). An impor-
tant methodological point gained from an initial study was the observation that PBZ had
essentially no biological effect if initially dissolved in DMSO.
Since PBZ has adequate aqueous solubility in the NCI60 assay conditions, their laboratory
changed the initial solution and dilution steps as follows: “we solubilized in water (to 0.004M),
transferred 75 μL to a dilution plate and sealed under argon in 20 minutes or less, and that
dilution plate was then diluted by adding 15 mL of media (in no more than 3 hrs from initial
solubilization), mixed and then immediately transferred 1:1 (100 μL into 100 μL) into growing
cells.” Anti-tumor activity was measured with the Sulforhodamine B assay (BioVision, Inc.,
Milpitas, CA). PBZ demonstrated biological activity under these assay conditions. The reason
for the lack of activity after dissolution in DMSO has not been pursued further, but DMSO
was eliminated in all subsequent assay systems.
Further studies with varying drug concentrations on selected human cell lines, in most
cases those studied in the NCI60 screen, were conducted by Oncotest GmbH laboratories,
Freiburg, Germany; Oncotest is a division of Charles River Laboratories. The dissolution pro-
cedure for PBZ and the cell culture assays conditions were similar to those at the NCI except
that the culture medium contained 10% FCS and the incubation period was 72 hours; anti-
tumor activity was determined with the CellTiter-Blue1 Cell Viability Assay, Promega, Mann-
heim, Germany. The 50% Inhibitory (IC50) concentrations were determined. The results are
the average of duplicate assays. Paclitaxel was included as a reference compound to confirm
the integrity of the assays. See S1 Appendix for further details.
Effects of PBZ on histone deacetylase activity. Assays of the effects of PBZ on the deace-
tylase activity of HDACs 1 thru 11 were carried out by BPS Bioscience Laboratories, San Diego
CA. PBZ was dissolved in isotonic phosphate-buffered saline (PBS) pH 7.4, at a concentration
of 100 μM in our laboratory. It was shipped in this solution to BPS Bioscience Laboratories.
The 100 μM stock solution was diluted with PBS for IC50 assays at the time of assay. The drug
was pre-incubated for 1 hour at 37˚C with the HDAC enzymes before addition of substrate.
No DMSO or bovine serum albumin was present in the assays. Fluorogenic acetylated lysine
peptides, according to the laboratories standard conditions and concentrations, were used as
substrates (as noted in the results); fluorescence is suppressed until the acetyl group is removed
by enzymatic activity, allowing a fluorescent measure of deacetylase activity. The assays were
completed during the day following their initial dissolution in PBS. IC50 values for PBZ and
SAHA or TSA (positive controls) were determined for each HDAC. See S2 Appendix for fur-
ther details.
Results
PBZ searches on the Harvard-MIT molecular signature database
The output from CMap identified a relatively potent gene enrichment score [20] for PBZ in
relation to a common core gene set resulting from inhibition by several HDACs in the human
breast cancer cells, MDA 468 and MDA 435, and in cells of T24 human bladder cancer [19].
The gene enrichment score for PBZ was 0.818, p = 0.00193; it ranked 14th in relation to an
enrichment score of 0.974 for MS-275, 0.973 for SAHA, 0.942 for scriptaid, and 0.895 for TSA,
all established HDAC inhibitors (Table 1). All of the remaining compounds listed in Table 1,
with the exception of pimozide (an anti-psychotic drug), have established or investigational
anti-proliferative mechanisms of action.
Phenoxybenazamine inhibits certain histone deacetylases
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When the “selectivity” option of CMap was used to probe the relation of PBZ to other gene
signatures in the MSigDB, the output produced a considerable list of gene enrichment scores
for PBZ that were greater than that presented in relation to the Glaser [19] signature, and gave
further evidence of possible association with various involvements in histone modifications
(Table 2). A total of 24 gene expression signatures were identified where PBZ showed compa-
rable or greater gene enrichment scores than TSA or SAHA. There were four groups of signa-
tures that were disproportionately represented: Ultraviolet radiation of the epidermis in the
low wavelength range (UVC); cytomegalovirus replication processes (CMV); ultraviolet radia-
tion in the intermediate wavelength range (UVB); and gene signatures resulting from exposure
of colon cancer cells to HDAC inhibitors.
In all of the gene signatures where comparisons were possible among the enrichment
scores for PBZ, TSA and SAHA, the scores for SAHA were greater than for TSA. SAHA
enrichment was greater than PBZ for only 3 gene signatures, HDACI_COLON _BUT24 HRS,
HDACI_COLON_BUT12HRS, and HDACI_COLON_TSA; TSA was greater than PBZ for
only the HDACI_BUT12HRS signature.
Effects of PBZ on human tumor cell proliferation
The CMap results formed the basis for an application to the NCI60 screening program for
anti-tumor efficacy. The results from that screen for PBZ at a 10 μM concentration are pre-
sented in Fig 2. PBZ showed a range of inhibitory activity on many of the cultures in NCI60
screen.
Several of the cultures that showed greater anti-tumor sensitivity to PBZ were studied fur-
ther at the laboratories of Oncotest GmbH (Table 3). There was uniformly more inhibitory
activity to PBZ when tested with 5% FCS for 48 hours (NCI60 assays) than with 10% FCS for
72 hours (Table 3).
An additional study was conducted with 1% FCS (Fig 3). This study included 3 additional
cell cultures that were not part of the NCI60 screen: CNXF U-251, a CNS tumor; LXFS DMS
Table 1. Rank order of gene enrichment score for phenoxybenzamine in relation to HDAC inhibitors.
CMap Name Enrichment Score p value
MS-275 0.974 0.00000
vorinostat 0.973 0.00109
rifabutin 0.971 0.00004
scriptaid 0.942 0.00024
5707885 0.913 0.00004
withaferin A 0.896 0.00010
trichostatin A 0.895 0.00000
suloctidil 0.888 0.00016
emetine 0.888 0.00016
ivermectin 0.858 0.00012
pimozide 0.852 0.00072
cephaeline 0.848 0.00018
cicloheximide 0.830 0.00127
phenoxybenzamine 0.818 0.00193
From Broad Institute Connectivity Map, in relation to gene signatures from reference [19] for bladder and breast
cancers.
https://doi.org/10.1371/journal.pone.0198514.t001
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Table 2. CMap SPECIFICITY: Phenoxybenzamine scored better with the following MSigDB gene sets than in the
Glaser gene set (Table 1), and is compared with scores for TSA and SAHA with the same gene sets.
PBZ Enrichment
Score Gene Set
0.998 UVC_TTD_8HR (TSA 0.472; SAHA 0.723)
0.995 UVC_XPCS_8HR (TSA 0.669; SAHA 0.888)
0.994 UVC_TTD-XPCS_COMMON
0.994 AS3_HEK293 (TSA 0.485; SAHA 0.674)
0.993 UVC_LOW_ALL
0.993 UVC_XPCS_ALL (TSA 0.680; SAHA 0.969)
0.991 UVC_TTD_ALL (TSA 0.489; SAHA 0.874)
0.990 CMV_UV- CMV_COMMON_ HCMV_6HRS (TSA 0.614; SAHA 0.863)
0.989 ET743_HELA (TSA 0.540; SAHA 0.642)
0.986 CMV_HCMV_6HRS
0.986 UVC_XPCS_4HR (TSA 0.470; SAHA 0.657)
0.982 CHEN_HOXA5_TARGETS
0.982 CMV_8HRS (TSA 0.588; SAHA 0.615)
0.978 ZHAN_MM_MOLECULAR_ CLASSI
0.977 CMV-UV_HCMV_6HRS (SAHA 0.937)
0.975 MIDDLEAGE
0.974 CMV_HCMV_TIMECOURSE_10HRS (SAHA 0.663)
0.972 UVC_TTD_4HR (SAHA 0.618)
0.970 CMV_HCMV_TIMECOURSE_ALL (TSA 0.478; SAHA 0.785)
0.969 OXSTRESS_BREASTCA
0.963 SHEPARD_CRASH_AND_BURN_MUT_VS_WT
0.963 CROONQUIST_IL6_RAS
0.962 UVC_HIGH_ALL (TSA 0.638; SAHA 0.794)
0.961 UV-CMV_UNIQUE_HCMV_6HRS
0.960 HBX_HCC
0.954 STRESS_ARSENIC_SPECIFIC
0.942 UVB_NHEK2 (TSA 0.598; SAHA 0.795)
0.941 BRCA1_OVEREXP_PROSTATE
0.935 GAY_YY1 (TSA 0.608; SAHA 0.786)
0.925 KNUDSEN_PMNS
0.922 ELONGINA_KO
0.919 ET743_SARCOMA_24HRS (TSA 0.554; SAHA 0.755)
0.916 SMITH_HTERT
0.912 UVB_NHEK1(TSA 0.559; SAHA 0.753)
0.909 HDACI_COLON_BUT24HRS (TSA 0.885; SAHA 0.976)
0.903 MUNSHI_MM_VS_PCS
0.896 NEMETH_TNF
0.893 CANTHARIDIN
0.891 KANNAN_P53
0.881 TPA_SENS_EARLY
0.876 WERNERONLY_FIBRO
0.872 CMV_HCMV_TIMECOURSE_12HRS
0.869 CAMPTOTHECIN_PROBCELL (TSA 0.514; SAHA 0.726)
0.869 IGFR_IR
0.868 HDACI_COLON_SUL
(Continued)
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273, a small-cell lung tumor; and LYXF DLBC SU-DHL-1, a lymphoma. The differences in
these assay conditions and their possible interactions were not systematically studied further.
Fig 3 includes the IC50 values for PBZ for each of the 9 cell cultures that were tested at 1%
FCS.
Table 2. (Continued)
PBZ Enrichment
Score Gene Set
0.866 PARP_KO (TSA 0.574; SAHA 0.769)
0.862 TAKEDA_NUP8_HOXA9_16D
0.855 HEDVAT_ELF
0.850 HDACI_COLON_BUT12HRS (TSA 0.882; SAHA 0.980)
0.844 GH_AUTOCRINE
0.836 PENG_LEUCINE(TSA 0.523)
0.823 HDACI_COLON_TSA (TSA 0.716; SAHA 0.889)
https://doi.org/10.1371/journal.pone.0198514.t002
Fig 2. Effects of PBZ on cellular proliferation in the NCI60 human tumor culture screen.
https://doi.org/10.1371/journal.pone.0198514.g002
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A summary of the 3 trials by Oncotest laboratories (Table 4) gives further evidence of the
effect of FCS concentration on PBZ inhibition, in particular in the assays with PBZ at 100 μM
concentration. Some evidence is also seen at a PBZ concentration of 32 μM. It may be specu-
lated that non-specific binding of PBZ to protein may have reduced the free concentration of
PBZ available for cellular interaction.
Table 3. Comparison of percent growth in several cell cultures in the presence of 10 μM phenoxybenzamine with 5% and 10% fetal calf serum and different incuba-
tion periods.
Cell line Tumor Class Percent cell growth in NCI60 screen with
5% FCS (48 hr incubation)
Percent cell growth in Oncotest screen
with 10% FCS (72 hr incubation)
LXFA NCI-H522 Non-Small-cell Lung 73 108
MAXF T47D Breast 60 97
MEFX UACC-257 Melanoma 76 107
MMXF RPMI 8226 Leukemia 60 98
OVXF OVCAR-8 Ovarian 53 90
PRXF PC-3 Prostate 63 86
https://doi.org/10.1371/journal.pone.0198514.t003
Fig 3. Effects of PBZ on cellular proliferation in 9 human tumor cell cultures of Oncotest laboratories with a medium containing 1%
FCS. Gradations of red color intensity in the list of cell lines increase with increasing degree of inhibition.
https://doi.org/10.1371/journal.pone.0198514.g003
Phenoxybenazamine inhibits certain histone deacetylases
PLOS ONE | https://doi.org/10.1371/journal.pone.0198514 June 13, 2018 9 / 18
Effects of PBZ on histone deacetylase activity
The inhibitory activity of PBZ on HDACs 1 thru 11 are presented in Fig 4.
HDAC6 was the most sensitive to PBZ, with an IC50 value of 0.59 μM. Next in sensitivity
were HDAC9 (IC50 5.3 μM) and HDAC5 (IC50 9.8 μM). These activities are also presented in
Fig 5 together with the inhibitory activity of TSA and SAHA for the same enzymes. HDACs 3,
7 and 8 showed inhibitions in the 30% range at 10 μM concentrations of PBZ.
Discussion
CMap gene expression enrichment values for PBZ relative to HDAC inhibitors for a varied
group of gene signatures (Table 2) greatly expanded the initial observation that co-sorted PBZ
with HDAC inhibitors for a common gene expression signature resulting from the effects of
SAHA, TSA and MS-275 in human breast cancer cells and human bladder cancer cells
(Table 1) [19]. Some of the highest PBZ enrichment scores that allowed comparisons with
SAHA and TSA enrichments (PBZ scores 0.998, 0.995, 0.994, 0.993, 0.991, 0.986, 0.972,
0.962) were found in MSigDB for ultraviolet exposure signatures in the low wavelength range,
100 to 280 nm, UVC class radiation. These signatures relate to both trichothiodystrophy
Table 4. Summary of PBZ effects on human tumor cell culture proliferation at two concentrations of FCS.
Phenoxybenzamine Test/Control (%) at Drug Concentration [uM]
Cell Line Study No. ECS Exp No 1,0E-03 3,2E-03 1,0E-02 3,2E-02 1,0E-01 3,2E-01 1,0E+00 3,2E+00 1,0E+01 3,2E+01 1,0E+02
CNXF U-251 P495A 10% QA1489-P1456245-5 - 85 90 93 90 93 92 94 103 118 98
- - - - - - - - - - - - - -
P495C 1% RA0214-P1537009-4 - - - - - - 98 102 102 98 36
LXFA
NCI-H522
P495A 10% QA1490-P1456251-5 - 76 81 82 96 98 99 107 108 110 14
P495B 10% QA1971 100 - 100 - 100 - 100 100 93 97 29
P495C 1% RA0214-P1537009-5 - - - - - - 99 106 99 89 6
LXFS
DMS273
P495A 10% QA1489-P1456245-6 - 83 75 74 81 80 76 87 82 100 105
- - - - - - - - - - - - - -
P495C 1% RA0215-P1536458-4 - - - - - - 104 101 91 100 49
LYXF
SU-DHL-1
P495A - - - - - - - - - - - -
P495B 10% QA1976 100 - 100 - 100 - 98 100 100 94 0
P495C 1% RA0218-P1537021-4 - - - - - - 97 96 91 45 7
MAX T47D P495A 10% QA1491-P1456274-4 - 97 92 92 97 97 101 102 97 95 74
P495B 10% QA1975 94 - 93 - 92 - 80 79 79 84 57
P495C 1% RA0215-P1536458-5 - - - - - - 98 99 96 92 37
MEXF
UACC-257
P495A 10% QA1489-P1456245-7 - 103 101 113 101 104 101 109 107 106 68
- - - - - - - - - - - - - -
P495C 1% RA0216-P1535660-4 - - - - - - 101 106 107 77 41
MMX
RPMI8226
P495A 10% QA1491-P1456274-5 - 86 80 76 83 84 89 87 98 99 10
P495B 10% QA1974 100 - 100 - 100 - 88 92 94 95 16
P495C 1% RA0218-P1537021-5 - - - - - - 102 101 95 77 5
OVXF
OVCAR-8
P495A 10% QA1490-P1456251-6 - 84 90 86 85 86 84 92 90 96 67
P495B 10% QA1972 92 - 90 - 86 - 89 84 82 74 32
P495C 1% RA0216-P1535660-5 - - - - - - 102 104 100 61 22
PRXF PC-3 P495A 10% QA1490-P1456251-7 - 91 83 87 87 91 86 89 86 82 52
P495B 10% QA1973 81 - 88 - 84 - 89 92 77 74 49
P495C 1% RA0217-P1537015-3 - - - - - - 102 105 100 58 22
https://doi.org/10.1371/journal.pone.0198514.t004
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Fig 4. Effects of PBZ on the activity of HDACs 1 thru 11.
https://doi.org/10.1371/journal.pone.0198514.g004
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(TTD) syndrome and xeroderma pigmentosum (XP) in combination with features of Cock-
ayne syndrome (XP/CS) [21,22]. Despite the fact that these syndromes appear to share certain
common defects in nucleotide excision repair competence (NER) there are distinct differences
in the clinical manifestations of the syndromes, limiting to some extent the absolute impor-
tance of NER in some features. A particular difference is that XP patients show a high fre-
quency of skin cancer, while TTD and CS patients have a low incidence of tumors; also, the CS
syndrome includes developmental and neurological abnormalities [21]. In view of the complex
genomics of these several syndromes, it is not surprising that there are conflicting reports on
the effects of HDAC inhibition on the efficiency of NER among these different but related
pathologies [23–27]. In the context of this present study, it is primarily of interest that PBZ
shows considerable concurrence with classical HDAC inhibitors in regard to gene enrichment
scores for UVC-related gene signatures.
PBZ scores 0.990, 0.982, 0.977, 0.974, and 0.970 in Table 2 provide data on human cyto-
megalovirus (HCMV) gene signatures that include comparative gene enrichment scores for
PBZ, TSA and SAHA. It is quite consistently seen that HDAC inhibition results in an
increased permissiveness for infection by HCMV and an increase in viral replication [28,29].
This aspect of histone modification with the use of TSA, SAHA, valproic acid and other inhibi-
tors has been applied in vitro and in vivo to increase the effectiveness of herpes-based oncolytic
cancer therapy [30–32]. It is interesting to speculate that PBZ may share some of this potential
therapeutic efficacy.
PBZ scores 0.942 and 0.912 can be compared with the enrichment scores for TSA and
SAHA for gene signatures resulting from ultraviolet exposure in the range of 280 to 320 nm,
UVB radiation. UVB radiation is considered to have the most energy and DNA damaging
potential of solar radiation. Exposure of normal epidermal keratinocytes (NHEK) to UVB
radiation produced the two signatures included in these comparisons, and has the potential to
proceed to basal cell or squamous cell carcinoma [33]. Of interest in relation to the enrichment
scores in Table 2, Simpson et al. [34] demonstrated that TSA, through an increased elaboration
of the cell adhesion protein, desmoglein 1,was able to prevent fragmentation of monolayers of
keratinocytes induced by an exfoliative bacterial toxin, Also, in a follow up on this work,
Fig 5. Comparison of the inhibitory activities of PBZ on HDACs 5, 6. and 9 with those for TSA and SAHA.
https://doi.org/10.1371/journal.pone.0198514.g005
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Johnson et al. [35] demonstrated that TSA was able to increase epidermal desmoglein 1 and
help recover markers of keratinocyte differentiation following UVB exposure.
Finally, PBZ scores 0.909 and 0.850 relate to gene signatures from colon cancer cells treated
with butyrate, and PBZ 0.823 score for cells treated with TSA. There is an extensive literature
on the effects of TSA, SAHA, valproic acid and sodium butyrate on colon cancer cell lines with
growth arrest, stimulation of maturation, and induction of apoptosis [36–39]. PBZ enrichment
scores for PBZ compared favorably with those of TSA and SAHA for these gene signatures.
The co-sorting of PBZ with other HDAC inhibitors for a number of gene signatures (Tables
1 and 2), and evidence of anti-proliferative effects on human tumor cell cultures (Figs 2 and 3,
and Tables 3 and 4) prompted studies that demonstrated HDAC inhibitory activity with PBZ
(Figs 4 and 5). A review of the literature through PubMed and other search resources did not
reveal any prior report or contention of PBZ as an HDAC inhibitor. However, there is prior
evidence of its potential anti-proliferative effects. Gheeya et al. demonstrated that epoxy
anthraquinone derivative (EAD) inhibited multiple cell lines of neuroblastoma cells by
inhibition of DNA replication through several mechanisms. Using CMap analysis to identify
potential agents with similar activity to EAD, PBZ showed a high gene enrichment score (con-
nectivity) relative to EAD [40]. The authors proposed that this might be related to a potential
DNA alkylating activity and/or alpha-adrenergic blockade. Wang et al. applied high-through-
put screening of the effects of 1280 small molecules on growth in two human neuroblastoma
cell lines [41]. PBZ was one of four compounds that showed dose-dependent inhibition of cell
growth, invasion and migration. It was suggested that these effects might be related to the cal-
modulin inhibitory activity of PBZ or its effects as an alpha- adrenergic antagonist.
Karube et al. [42] used CMap analyses in search of candidate drugs with potential efficacy
against NK cell neoplasms (lymphoid cancers). PBZ was rated with a high negative gene
enrichment score in their map, suggesting possible therapeutic value in these malignancies.
The inhibitory potency of PBZ was considerably lower than that for puromycin, SAHA and
TSA in cellular assays; most of the work was therefore centered on SAHA. It is of interest that
the drugs, including PBZ, were dissolved and diluted in DMSO; as noted above, DMSO
appeared to interfere with PBZ potency in the current work.
Two papers focused on the involvement of PBZ in proliferative processes in the central ner-
vous system. Cobret et al. [43] identified PBZ in a screen of 1263 small molecular weight mole-
cules as having the highest complex formation with LINGO-1, which negatively regulates
neuritic growth and survival of neurons. LINGO-1 is found only in neuronal tissue as part of a
plasma membrane and endoplasmic reticulum complex with apparent receptor function and
molecular signaling properties. Its ligand complex with PBZ enhances its negative regulation
of growth and survival [43]. These observations were extended by the recent report of Lin et al.
[44] demonstrating anti-proliferative effects of PBZ in U251 and U87MG malignant glioma
cell lines. They demonstrated inhibitory effects on proliferation, invasion and migration in in-
vitro studies, and a marked reduction in expansion of tumor volume in vivo with the direct
injection of PBZ into implanted tumors. Western blot analysis showed a marked increase in
LINGO-1 expression in U251 cells following PBZ treatment, which may explain its negative
proliferative effects.
Lee [45] observed a marked inhibitory effect of PBZ on the cellular proliferative activity of
vascular smooth muscle that leads to the development of pulmonary arterial hypertension
(PAH) in a rat model. The vascular remodeling primarily involved medial thickening of pul-
monary arterioles, with severe narrowing of the vascular channel; the obstructive nature of this
remodeling leads to a greatly heightened afterload against right- ventricular outflow, with a
resulting right-ventricular hypertrophy and eventual right-heart cardiac failure. The two most
common animal models of PAH involve chronic hypoxic ventilation or administration of the
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pulmonary toxin, monocrotaline. Lee found that daily injections of PBZ following treatment
with monocrotaline resulted in a 69% decrease in right-ventricular hypertrophy and an 80%
inhibition in the increase in medial thickening of pulmonary arteries after 4 weeks of PBZ
treatment. Relevance to the present study is found in that HDAC inhibition has drawn consid-
erable recent consideration in experimental models of PAH, especially in regard to the impor-
tance of utilization of specific classes of inhibitors to obtain a net beneficial clinical result [46].
Kim et al. [47] demonstrated that specific HDAC IIa inhibition was able to substantially
reverse established PAH in both monocrotoline and hypoxic animal models.
It is not possible to propose clinical translation of the observations in these present studies
of an HDAC inhibitory activity of PBZ. However, the examples of anti-proliferative actions of
PBZ noted above may warrant interest in this connection. PBZ showed fairly significant inhib-
itory potential among both Class IIa (HDAC5, HDAC9) and Class IIb (HDAC6) isoforms
(Figs 4 and 5). In addition, the inhibition of HDACs 3, 7 and 8 in the 30% range at 10 μM con-
centration may contribute, in part, to the range of inhibitory activity that was seen in the
NCI60 tumor cell culture screen (Fig 2).
The inhibitory potencies of PBZ on HDAC5 (IC50 9.8 μM) and on HDAC9 (IC50 5.3 μM)
(Fig 5) were fairly comparable to the potencies of TSA in these assays, i.e., IC50 4.6 μM and
IC50 5.0 μM respectively, for TSA. And, PBZ was more potent than SAHA in inhibition of
both HDAC 5 and 9 (Fig 5). These results may be of interest in relation to the associations that
were identified for PBZ with known HDAC inhibitors in the CMap findings (Tables 1 and 2).
High levels of expression of HDAC5 and HDAC9 mRNA and protein in primary pediatric
medulloblastoma tumors are associated with poor survival; also, transfection with multiple
siRNAs for HDAC5 and 9 in established tumor cell lines caused a reduction in cell prolifera-
tion in all of the transfection vectors that were studied [48]. HDAC5 mRNA and protein
expression in breast cancer are known to promote metastasis and to be important negative
prognosticators of survival [49]. The potency of PBZ on HDAC 5 and 9 (Fig 5) relative to that
of other established HDAC inhibitors suggests potential areas for further studies.
PBZ showed the highest potency against HDAC6 under the conditions of these present
assays (Figs 4 and 5). This is of interest in relation to the possible association that we and others
have found for the use of the drug in neuropathic pain syndromes [2,4,5]. Studies by Kru-
kowski et al. [50] demonstrated that a highly selective HDAC6 inhibitor, ACY-1083, showed a
remarkable capacity to both prevent and reverse the peripheral neuropathy induced by treat-
ment with cisplatin in mice. The HDAC6 inhibitor normalized the sensitivity threshold for
pain (paw withdrawal), an established measure of mechanical allodynia. Increased acetylation
of α- tubulin in peripheral nerve, restoration of mitochondrial energetics in peripheral nerves
and dorsal root ganglia, and, with prolonged treatment, restoration of intra-epidermal inner-
vation of the paw were observed. Certain aspects of these results were confirmed in mice with
administration of larger doses of a less potent HDAC6 inhibitor, ACY-1215, following a course
of treatment with cisplatin.
PBZ may have an advantage in relation to possible new applications in that it has been
in clinical use since approval by the FDA in 1953. The drug is only labeled for one use, treat-
ment of paroxysmal hypertension and sweating in patients with a pheochromocytoma. The
drug is clinically recognized as appropriate for off-label applications in the treatment of
several urinary tract conditions, including benign prostatic hypertrophy, neurogenic bladder,
micturation disorders, prostatitis and post-operative urinary retention following epidural
administration of morphine [1,51]. In an extensive review of the clinical use of PBZ, Te [51]
estimated that over 20,000 patients in the United States alone received PBZ during the period
from 1953 to 2002. The drug has relatively mild adverse effects that are expected in relation to
its α-adrenergic blocking activity. The more common include nasal congestion, dizziness from
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postural hypotension accompanied by tachycardia, and miosis. These effects usually decrease
with continued therapy. Fatigue, confusion, headache, inhibition of ejaculation, and gastroin-
testinal symptoms occur with less frequency or rarely [1,51]. PBZ carries a warning of muta-
genic and carcinogenic activity, but in its long clinical use there appears to be no established
evidence of a cancer risk with this drug at this time [1,5,51]. The minor adverse effect profile of
PBZ may have an advantage over some HDAC inhibitors.
In view of the FDA-approved status of the drug, it may be possible to test the drug in an
appropriate case where there is a poor clinical prognosis and first-line therapies have been
exhausted, or through an FDA Investigational Drug Application for an off-label treatment
protocol.
Conclusions
The patterns of gene expression that were induced by PBZ in several tumor cell lines (Broad-
Build02 Molecular Signature Database) suggested that this drug may have HDAC inhibitory
activity. Inhibition of HDACs 5, 6, and 9 reached potencies that may suggest a value for further
investigations, especially since the drug is already FDA approved and has a long clinical history.
The limitations of the present studies are that they did not explore whether the inhibition of cer-
tain HDACs by PBZ had a direct relationship to the suppression of tumor growth rates by the
drug, nor did they establish a clinical translation. These questions require further investigation.
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